Implant Sciences’ QS-B220 Explosives Trace Detector Receives Department of Homeland Security’s Safety Act DT&E

Glenn D. Bolduc, Implant Sciences’ President and CEO, stated, “We see the QS-B220 bench-top detector as a critical tool in a multi-layered security environment at U.S. points of entry, including airports. Receiving DT&E Designation is a key milestone for our explosives and narcotics trace detection product. We will work diligently with the Department of Homeland Security and our key customers and partners where the QS-B220 is now being evaluated for use in multilayer security solutions.”

For more information about the SAFETY Act and the Department of Homeland Security’s DT&E Designation under the Safety Act, please see

www.safetyact.gov.

About the Quantum Sniffer QS-B220

The Quantum Sniffer QS-B220, introduced in May 2011, is a bench-top explosives and narcotics trace detector that uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, improvised, or homemade explosives and narcotic substances. The QS-B220 continues the Implant Sciences tradition of freedom from radioactive materials, low total cost of ownership, and high operational availability.

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences’ QS-H150 Portable Explosives Detector has been designated as Qualified Anti-Terrorism. Technology by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company’s website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain “forward-looking statements,” as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management’s current expectations and are subject to risks and uncertainties that could cause the Company’s actual results to differ materially from the forward-looking statements.

Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the U.S. government or by other law enforcement agencies or commercial consumers of security products; the risk that liability claims related to our products or our handling of hazardous materials could damage our reputation and have a material adverse effect on our financial results; the fact that our

business is subject to intense competition and rapid technological change; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management’s current expectations and assumptions which could differ materially from the forward-looking statements.

Contact:

Implant Sciences Corporation
Company Contact:Glenn Bolduc
CEO
978-752-1700
gbolduc@implantsciences.com
or

Investor Contact:
Laurel Moody
646-810-0608
lmoody@corporateprofile.com
Copyright 2011, Market Wire, All rights reserved.